ART 5803
Alternative Names: ART-5803Latest Information Update: 23 Jun 2025
At a glance
- Originator Arialys Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Anti-N-methyl-D-aspartate-receptor-encephalitis
Most Recent Events
- 18 Jun 2025 Pharmacodynamics data from a preclinical studies in Anti-N-methyl-D-aspartate receptor encephalitis released by Arialys Therapeutics
- 18 Mar 2025 Arialys Therapeutics initiates a phase I trial for Anti-N-methyl-D-aspartate receptor encephalitis (In volunteers) in Australia (IV, Infusion) (NCT06753955)
- 26 Feb 2025 Safety and pharmacokinetics data from a phase I trial in Anti-N-methyl-D-aspartate receptor encephalitis released by Arialys Therapeutics